Prevalence of adverse events in cystic fibrosis patients treated with elexacaftor/tezacaftor/ivacaftor: Experience of the regional referral center in Tuscany, Italy-Reference-Cited by-同舟云学术

Prevalence of adverse events in cystic fibrosis patients treated with elexacaftor/tezacaftor/ivacaftor: Experience of the regional referral center in Tuscany, Italy

Published:2023-09-26 Issue:12 Volume:58 Page:3626-3629
ISSN:8755-6863
Container-title:Pediatric Pulmonology
language:en
Short-container-title:Pediatric Pulmonology

Author:

Manciulli Tommaso¹^ORCID,Bresci Silvia²,Mencarini Jessica²,Avarello Angelo²,Taccetti Giovanni³,Terlizzi Vito³^ORCID

Affiliation:

1. Department of Experimental and Clinical Medicine University of Florence Florence Italy

2. Infectious and Tropical Diseases Unit Careggi University Hospital Florence Italy

3. Department of Paediatric Medicine Meyer Children's Hospital IRCCS, Cystic Fibrosis Regional Reference Center Florence Italy

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Pediatrics, Perinatology and Child Health

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ppul.26673

Reference8 articles.

1. Effectiveness and safety of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease with the Phe508del/minimal function genotype

2. VX-445–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles

3. Impact of elexacaftor/tezacaftor/ivacaftor on depression and anxiety in cystic fibrosis

4. Onset of systemic arterial hypertension after initiation of elexacaftor/tezacaftor/ivacaftor in adults with cystic fibrosis: A case series

5. Incidence of transaminitis in adults with cystic fibrosis taking elexacaftor/tezacaftor/ivacaftor

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Reported Adverse Events in a Multicenter Cohort of Patients Ages 6-18 Years with Cystic Fibrosis and at Least One F508del Allele Receiving Elexacaftor/Tezacaftor/Ivacaftor;The Journal of Pediatrics;2024-11

2. Update on advances in cystic fibrosis towards a cure and implications for primary care clinicians;Current Problems in Pediatric and Adolescent Health Care;2024-06